Nxera Pharma: Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ in Japan
Nxera Pharma: Notice of a new partnership with Shionogi Pharmaceutical regarding the insomnia remedy “Kubivic tablets” targeting the Japanese market
Nxera Pharma: Articles of Incorporation 2024/04/01
Nxera Pharma: Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
Nxera Pharma: We have received a USD 35 million milestone from Neurocline due to the positive results of the Phase 2 clinical trial of the candidate NBI-1117568 for schizophrenia
Nxera Pharma: Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
Nxera Pharma: Good results in phase 2 clinical trials of schizophrenia drug candidate NBI-1117568, which is a partnership program with Neurocline
Nxera Pharma: Change Report
Nxera Pharma: Amended Securities Registration Statement (Reference Method)
Nxera Pharma: Amended Securities Registration Statement (Reference Method)
Nxera Pharma: Corrected securities registration form (reference method)
Nxera Pharma: Corrected securities registration form (reference method)
Nxera Pharma: Confirmatory letter.
Nxera Pharma: Interim report - 35th period (01/01/2024 - 12/31/2024)
Nxera Pharma: Business highlights and consolidated performance for the second quarter (interim period) of December 2024 (January-June).
Nxera Pharma: Consolidated financial results (IFRS) for the six-month period ending on June 30, 2024.
Nxera Pharma: December 2024, second quarter (interim period) financial results announcement [IFRS] (consolidated).
Nxera Pharma: Business highlights and consolidated performance for the second quarter and first half of 2024 for Nxera Pharma.
Nxera Pharma: Change Report (Stock Certificates Eligible for Special Provisions, etc.)
Nxera Pharma: Change Report (Stock Certificates Eligible for Special Provisions, etc.)
No Data
No Data